Annals of Behavioral Medicine

, Volume 27, Issue 1, pp 68–79

Human papillomavirus and cervical cancer: Issues for biobehavioral and psychosocial research

  • Jo Waller
  • Kirsten J. McCaffery
  • Sue Forrest
  • Jane Wardle
Article

Abstract

There is now overwhelming evidence that high-risk, sexually transmitted types of human papillomavirus (HPV) are the main causal agent in cervical cancer. Biobehavioral and psychosocial research is uniquely capable of addressing many of the issues raised by HPV and its link with cervical cancer. In this article we review current findings in this area and identify issues for future research. The first of the three sections explores issues associated with the introduction of HPV testing for the detection and management of cervical abnormalities and the impact of growing public awareness of the sexually transmitted nature of cervical cancer. The implications for public understanding of cervical cancer, psychosocial issues associated with screening, and the potential impact on screening uptake are discussed. The second section addresses the role of biobehavioral factors in the persistence and progression of HPV infection as well as possible interventions to minimize the risk of persistence. Finally, primary prevention of HPV is discussed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. (1).
    Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer.Journal of Clinical Pathology. 2002,55:244–265.PubMedGoogle Scholar
  2. (2).
    Franco EL, Rohan TE, Villa LL: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer.Journal of the National Cancer Institute. 1999,91:506–511.PubMedCrossRefGoogle Scholar
  3. (3).
    Bosch FX, Manos MM, Munoz N, et al.: Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.Journal of the National Cancer Institute. 1995,87:796–802.PubMedCrossRefGoogle Scholar
  4. (4).
    Lorincz AT, Temple GF, Kurman RJ, Jenson AB, Lancaster WD: Oncogenic association of specific human papillomavirus types with cervical neoplasia.Journal of the National Cancer Institute. 1987,79:671–677.PubMedGoogle Scholar
  5. (5).
    Cox JT: Epidemiology of cervical intraepithelial neoplasia: The role of human papillomavirus.Baillieres Clinical Obstetrics and Gynaecology. 1995,9:1–37.CrossRefGoogle Scholar
  6. (6).
    van Oortmarssen GJ, Habbema JD: Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears.International Journal of Epidemiology. 1995,24:300–307.PubMedCrossRefGoogle Scholar
  7. (7).
    Moscicki AB, Hills N, Shiboski S, et al.: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.Journal of the American Medical Association. 2001,285:2995–3002.PubMedCrossRefGoogle Scholar
  8. (8).
    Santos C, Munoz N, Klug S, et al.: HPV types and cofactors causing cervical cancer in Peru.British Journal of Cancer. 2001,85:966–971.PubMedCrossRefGoogle Scholar
  9. (9).
    Buchanan J, Nieland-Fisher NS: Role of immune function in human papillomavirus infection.Journal of the American Medical Association. 2001,286:1173–1174.PubMedCrossRefGoogle Scholar
  10. (10).
    Sun XW, Kuhn L, Ellerbrock TV, et al.: Human papillomavirus infection in women infected with the human immunodeficiency virus.New England Journal of Medicine. 1997,337:1343–1349.PubMedCrossRefGoogle Scholar
  11. (11).
    Carr J, Gyorfi T: Human papillomavirus. Epidemiology, transmission, and pathogenesis.Clinics In Laboratory Medicine. 2000,20:235–255.PubMedGoogle Scholar
  12. (12).
    Centers for Disease Control and Prevention:Tracking the Hidden Epidemics: Trends in STDs in the United States 2000. Atlanta: Department of Health and Human Services, Division of Sexually Transmitted Disease Prevention, 2000.Google Scholar
  13. (13).
    IARC: Human papillomaviruses.IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1995,64:35–86.Google Scholar
  14. (14).
    Konya J, Dillner J: Immunity to oncogenic human papillomaviruses.Advances In Cancer Research. 2001,82:205–238.PubMedGoogle Scholar
  15. (15).
    Stubenrauch F, Laimins LA: Human papillomavirus life cycle: active and latent phases.Seminars In Cancer Biology. 1999,9:379–386.PubMedCrossRefGoogle Scholar
  16. (16).
    Man S: Human cellular immune responses against human papillomaviruses in cervical neoplasia.Expert Reviews in Molecular Medicine. 1998. Retrieved November3, 2003, from http://www.ermm.cbcu.cam.ac.uk/smc/txt001smc.htmGoogle Scholar
  17. (17).
    Arnold K: Vaccines: The next step for cervical cancer prevention?Journal of the National Cancer Institute. 2001,93:260.CrossRefGoogle Scholar
  18. (18).
    zur Hausen H: Cervical carcinoma and human papillomavirus: On the road to preventing a major human cancer.Journal of the National Cancer Institute. 2001,93:252–253.PubMedCrossRefGoogle Scholar
  19. (19).
    Man S, Fiander A: Immunology of human papillomavirus infection in lower genital tract neoplasia.Best Practice & Research Clinical Obstetrics & Gynaecology. 2001,15:701–714.CrossRefGoogle Scholar
  20. (20).
    Cuzick J, Sasieni P: Estimates of the cost impact of introducing HPV testing into a cervical screening programme. In Franco E, Monsonego J. (eds),New Developments in Cervical Cancer Screening and Prevention. Oxford, England: Blackwell Sciences, 1997, 364–372.Google Scholar
  21. (21).
    Cuzick J, Sasieni P, Davies P, et al.: A systematic review of the role of human papillomavirus testing within a cervical screening programme.Health Technology Assessments. 1999,3:i-196.Google Scholar
  22. (22).
    Trofatter {jrJr.} KF: Diagnosis of human papillomavirus genital tract infection.American Journal of Medicine. 1997,102:21–27.PubMedCrossRefGoogle Scholar
  23. (23).
    Hildesheim A, Schiffman MH, Gravitt PE, et al.: Persistence of type-specific human papillomavirus infection among cytologically normal women.Journal of Infectious Diseases. 1994,169:235–240.PubMedGoogle Scholar
  24. (24).
    Sasieni P, Cuzick J: Could HPV testing become the sole primary cervical screening test?Journal of Medical Screening. 2002,9:49–51.PubMedCrossRefGoogle Scholar
  25. (25).
    Wright {jrJr.} TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ: 2001 consensus guidelines for the management of women with cervical cytological abnormalities.Journal of the American Medical Association. 2002,287:2120–2129.PubMedCrossRefGoogle Scholar
  26. (26).
    Solomon D, Schiffman M, Tarone R: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial.Journal of the National Cancer Institute. 2001,93:293–299.PubMedCrossRefGoogle Scholar
  27. (27).
    Wise J: UK pilot scheme for HPV testing announced.BMJ. 2000,320:600.PubMedCrossRefGoogle Scholar
  28. (28).
    Little J: Effectiveness of testing for high risk HPV for triage of low grade abnormal smears is being assessed in TOMBOLA trial.BMJ. 2001,323:109.PubMedCrossRefGoogle Scholar
  29. (29).
    Franceschi S, Herrero R, La Vecchia C: Cervical screening in Europe: What next?European Journal of Cancer. 2000,36:2272–2275.PubMedCrossRefGoogle Scholar
  30. (30).
    Watson R: European women’s group calls for human papillomavirus testing.BMJ. 2001,323:772.PubMedCrossRefGoogle Scholar
  31. (31).
    Ramirez JE, Ramos DM, Clayton L, Kanowitz S, Moscicki AB: Genital human papillomavirus infections: Knowledge, perception of risk, and actual risk in a nonclinic population of young women.Journal of Women’s Health. 1997,6:113–121.PubMedGoogle Scholar
  32. (32).
    Fernandez-Esquer ME, Ross MW, Torres I: The importance of psychosocial factors in the prevention of HPV infection and cervical cancer.International Journal of STD and AIDS. 2000,11:701–713.PubMedCrossRefGoogle Scholar
  33. (33).
    Miller S, Mischel W, O’Leary A, Mills M: From Human Papillomavirus to cervical cancer: Psychosocial processes in infection, detection and control.Annals of Behavioral Medicine. 1996,18:219–228.CrossRefPubMedGoogle Scholar
  34. (34).
    Vail-Smith K, White DM: Risk level, knowledge, and preventive behavior for human papillomaviruses among sexually active college women.Journal of American College Health. 1992,40:227–230.PubMedCrossRefGoogle Scholar
  35. (35).
    Yacobi E, Tennant C, Ferrante J, Pal N, Roetzheim R: University students’ knowledge and awareness of HPV.Preventive Medicine. 1999,28:535–541.PubMedCrossRefGoogle Scholar
  36. (36).
    Lambert EC: College students’ knowledge of human papillomavirus and effectiveness of a brief educational intervention.Journal of the American Board of Family Practice. 2001,14:178–183.PubMedGoogle Scholar
  37. (37).
    Baer H, Allen S, Braun L: Knowledge of human papillomavirus infection among young adult men and women: Implications for health education and research.Journal of Community Health. 2000,25:67–78.PubMedCrossRefGoogle Scholar
  38. (38).
    Dell DL, Chen H, Ahmad F, Stewart DE: Knowledge about human papillomavirus among adolescents.Obstetrics and Gynecology. 2000,96:653–656.PubMedCrossRefGoogle Scholar
  39. (39).
    Gerhardt CA, Pong K, Kollar LM, Hillard PJ, Rosenthal SL: Adolescents’ knowledge of human papillomavirus and cervical dysplasia.Journal of Pediatric and Adolescent Gynecology. 2000,13:15–20.PubMedCrossRefGoogle Scholar
  40. (40).
    Mays RM, Zimet GD, Winston Y, et al.: Human papillomavirus, genital warts, Pap smears, and cervical cancer: Knowledge and beliefs of adolescent and adult women.Health Care for Women International. 2000,21:361–374.PubMedCrossRefGoogle Scholar
  41. (41).
    Pitts M, Clarke T: Human papillomavirus infections and risks of cervical cancer: What do women know?Health EducationResearch. 2002,17:706–714.Google Scholar
  42. (42).
    Waller J, McCaffery KJ, Forrest S, et al.: Awareness of human papillomavirus (HPV) among women attending a well woman clinic.Sexually Transmitted Infections. 2003,79:320–322.PubMedCrossRefGoogle Scholar
  43. (43).
    Philips Z, Johnson S, Avis M, Whynes DK: Human papillomavirus and the value of screening: Young women’s knowledge of cervical cancer.Health Education Research. 2003,18:318–328.PubMedCrossRefGoogle Scholar
  44. (44).
    Breslow RA, Sorkin JD, Frey CM, Kessler LG: Americans’ knowledge of cancer risk and survival.Preventive Medicine. 1997,26:170–177.PubMedCrossRefGoogle Scholar
  45. (45).
    Wardle J, Waller J, Brunswick N, Jarvis MJ: Awareness of risk factors for cancer among British adults.Public Health. 2001,115:173–174.PubMedCrossRefGoogle Scholar
  46. (46).
    Gregory S, McKie L: Researching cervical cancer: Compromises, practices and beliefs.Journal of Advances in Health and Nursing Care. 1992,2:73–84.Google Scholar
  47. (47).
    Summers A: Mental health consequences of cervical screening.Psychology, Health and Medicine. 1998,3:113–126.CrossRefGoogle Scholar
  48. (48).
    Division of STD Prevention:Prevention of Genital Hpv Infection and Sequelae: Report of an External Consultants ’Meeting. Atlanta: Department of Health and Human Services, Centers for Disease Control and Prevention, 1999.Google Scholar
  49. (49).
    Cameron LD: Screening for cancer: illness perceptions and illness worry. In Petrie KJ, Weinman J (eds),Perceptions of Health and Illness. London: Harwood Academic, 1997, 291–321.Google Scholar
  50. (50).
    Raffle AE: Honesty about new screening programmes is best policy.BMJ. 2000,320:872.PubMedCrossRefGoogle Scholar
  51. (51).
    Raffle AE: Information about screening— is it to achieve high uptake or to ensure informed choice?Health Expectations. 2001,4:92–98.PubMedCrossRefGoogle Scholar
  52. (52).
    General Medical Council: Seeking Patients’ Consent: The Ethical Considerations. London: General Medical Council, 1998.Google Scholar
  53. (53).
    McCaffery KJ, Waller J, Forrest S, Wardle J: Testing for human papillomavirus in women with abnormal Pap smear results.Journal of the American Medical Association. 2002,288:1350–1352.PubMedCrossRefGoogle Scholar
  54. (54).
    Jenkins D: Diagnosing human papillomaviruses: Recent advances.Current Opinion in Infectious Diseases. 2001,14:53–62.PubMedCrossRefGoogle Scholar
  55. (55).
    Campion MJ, Brown JR, McCance DJ, et al.: Psychosexual trauma of an abnormal cervical smear.British Journal of Obstetrics and Gynaecology. 1988,95:175–181.PubMedGoogle Scholar
  56. (56).
    Wilkinson C, Jones JM, McBride J: Anxiety caused by abnormal result of cervical smear test: A controlled trial.BMJ. 1990,300:440.PubMedGoogle Scholar
  57. (57).
    Bell S, Porter M, Kitchener H, et al.: Psychological response to cervical screening.Preventive Medicine. 1995,24:610–616.PubMedCrossRefGoogle Scholar
  58. (58).
    Maw RD, Reitano M, Roy M: An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle.International Journal of STD and AIDS. 1998,9:571–578.PubMedCrossRefGoogle Scholar
  59. (59).
    Filiberti A, Tamburini M, Stefanon B, et al.: Psychological aspects of genital human papillomavirus infection: A preliminary report.Journal of Psychosomatic Obstetrics and Gynaecology. 1993,14:145–152.PubMedCrossRefGoogle Scholar
  60. (60).
    Clarke P, Ebel C, Catotti DN, Stewart S: The psychosocial impact of human papillomavirus infection: implications for health care providers.International Journal of STD and AIDS. 1996,7:197–200.PubMedCrossRefGoogle Scholar
  61. (61).
    Reed BD, Ruffin MT, Gorenflo DW, Zazove P: The psychosexual impact of human papillomavirus cervical infections.Journal of Family Practice. 1999,48:110–116.PubMedGoogle Scholar
  62. (62).
    Fylan F: Screening for cervical cancer: A review of women’s attitudes, knowledge, and behaviour.British Journal of General Practice. 1998,48:1509–1514.PubMedGoogle Scholar
  63. (63).
    Duncan B, Hart G, Scoular A, Bigrigg A: Qualitative analysis of psychosocial impact of diagnosis of Chlamydiatrachomatis: implications for screening.BMJ. 2001,322:195–199.PubMedCrossRefGoogle Scholar
  64. (64).
    Nack A: Damaged goods: Women managing the stigma of STDs.Deviant Behavior. 2000,21:95–121.CrossRefGoogle Scholar
  65. (65).
    Redfern N, Hutchinson S: Women’s experiences of repetitively contracting sexually transmitted diseases.Health Care for Women International. 1994,15:423–433.PubMedCrossRefGoogle Scholar
  66. (66).
    Holgate HS, Longman C: Some peoples’ psychological experiences of attending a sexual health clinic and having a sexually transmitted infection.Journal of the Royal Society of Health. 1998,118:94–96.PubMedCrossRefGoogle Scholar
  67. (67).
    Gilmore N, Somerville MA: Stigmatization, scapegoating and discrimination in sexually transmitted diseases: Overcoming “them” and “us”.Social Science and Medicine. 1994,39:1339–1358.PubMedCrossRefGoogle Scholar
  68. (68).
    Keller ML, von Sadovszky V, Pankratz B, Hermsen J: Self-disclosure of HPV infection to sexual partners.Western Journal of Nursing Research. 2000,22:285–296.PubMedCrossRefGoogle Scholar
  69. (69).
    Duncan B, Hart G, Scoular A: Screening and the construction of scepticism: the case of chlamydia.Health. 2001,5:165–185.CrossRefGoogle Scholar
  70. (70).
    Kavanagh AM, Broom DH: Embodied risk: My body, myself?Social Science and Medicine. 1998,46:437–444.PubMedCrossRefGoogle Scholar
  71. (71).
    Miller SM, Rodoletz M, Mangan CE, Schroeder CM, Sedlacek TV: Applications of the monitoring process model to coping with severe long- term medical threats.Health Psychology. 1996,15:216–225.PubMedCrossRefGoogle Scholar
  72. (72).
    Kavanagh AM, Broom DH: Women’s understanding of abnormal cervical smear test results: A qualitative interview study.BMJ. 1997,314:1388–1391.PubMedGoogle Scholar
  73. (73).
    Petrie KJ, Booth RJ, Pennebaker JW, Davison KP, Thomas MG: Disclosure of trauma and immune response to a hepatitis B vaccination program.Journal of Consulting and Clinical Psychology. 1995,63:787–792.PubMedCrossRefGoogle Scholar
  74. (74).
    Pennebaker JW, Kiecolt-Glaser JK, Glaser R: Disclosure of traumas and immune function: health implications for psychotherapy.Journal of Consulting and Clinical Psychology. 1988,56:239–245.PubMedCrossRefGoogle Scholar
  75. (75).
    American Cancer Society:Cancer Prevention & Early Detection: Facts and Figures 2002. Atlanta: American Cancer Society, 2002.Google Scholar
  76. (76).
    Cancer Screening Programmes: Informing Choice in Cervical Screening: Cervical Screening Programme Annual Review 2001. London: National Health Service Cervical Screening Programme, 2001.Google Scholar
  77. (77).
    Barth KR, Cook RL, Downs JS, Switzer GE, Fischhoff B: Social stigma and negative consequences: factors that influence college students’ decisions to seek testing for sexually transmitted infections.Journal of American College Health. 2002,50:153–159.PubMedCrossRefGoogle Scholar
  78. (78).
    van der Pligt J: Perceived risk and vulnerability as predictors of precautionary behaviour.British Journal of Health Psychology. 1998,3:1–14.Google Scholar
  79. (79).
    Bish A, Sutton S, Golombok S: Predicting uptake of a routine cervical smear test: A comparison of the health belief model and the theory of planned behaviour.Psychology and Health. 2000,15:35–50.CrossRefGoogle Scholar
  80. (80).
    Orbell S: Cognition and affect after cervical screening: The role of previous test outcome and personal obligation in future uptake expectations.Social Science and Medicine. 1996,43:1237–1243.PubMedCrossRefGoogle Scholar
  81. (81).
    Howson A: Cervical screening, compliance and moral obligation.Sociology of Health and Illness. 1999,21:401–425.CrossRefGoogle Scholar
  82. (82).
    De Sanjose S, Bosch FX, Munoz N, Shah K: Social differences in sexual behaviour and cervical cancer.IARC Scientific Publications. 1997,138:309–317.PubMedGoogle Scholar
  83. (83).
    Bentham G, Hinton J, Haynes R, Lovett A, Bestwick C: Factors affecting non-response to cervical cytology screening in Norfolk, England.Social Science andMedicine. 1995,40:131–135.CrossRefGoogle Scholar
  84. (84).
    Health Education Authority:A Survey of the UK Population, Part 1. London: Health Education Authority, 1995.Google Scholar
  85. (85).
    Wain G, Morrell S, Taylor R, Mamoon H, Bodkin N: Variation in cervical cancer screening by region, socio-economic, migrant and indigenous status in women in New South Wales.Australian and New Zealand Journal of Obstetrics and Gynaecology. 2001,41:320–325.PubMedCrossRefGoogle Scholar
  86. (86).
    Cervical Screening Programme, England: 1999-2000 (Lancucki L, Sheerman-Chase D, Wise S, eds). 2000/30. {plLondon}: Department of Health. Retrieved November 3, 2003, from http://www.doh.gov.uk/public/sb0030.htmGoogle Scholar
  87. (87).
    Health Education Authority:Black and Minority Ethnic Groups in England: Health and Lifestyles. London: Health Education Authority, 1994.Google Scholar
  88. (88).
    Sutton GC, Storer A, Rowe K: Cancer screening coverage of south Asian women in Wakefield.Journal of Medical Screening. 2001,8:183–186.PubMedCrossRefGoogle Scholar
  89. (89).
    Gupta A, Kumar A, Stewart DE: Cervical cancer screening among South Asian women in Canada: the role of education and acculturation.Health Care for Women International. 2002,23:123–134.PubMedCrossRefGoogle Scholar
  90. (90).
    Taylor RJ, Mamoon HA, Morrell SL, Wain GV: Cervical screening in migrants to Australia.Australian and New Zealand Journal of Public Health. 2001,25:55–61.PubMedGoogle Scholar
  91. (91).
    Elam G, Fenton K, Johnson A, Nazroo J, Ritchie J:Exploring Ethnicity and Sexual Health. London: Social and Community Planning Research, 1999.Google Scholar
  92. (92).
    McCaffery KJ, Forrest S, Waller J, et al.: Attitudes towards HPV testing: A qualitative study of beliefs among Indian, Pakistani, African Caribbean and white British women in the UK.British Journal of Cancer. 2003,88:42–46.PubMedCrossRefGoogle Scholar
  93. (93).
    Woodman CB, Collins S, Winter H, et al.: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.Lancet. 2001,357:1831–1836.PubMedCrossRefGoogle Scholar
  94. (94).
    Schlecht NF, Kulaga S, Robitaille J, et al.: Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.Journal of the American Medical Association. 2001,286:3106–3114.PubMedCrossRefGoogle Scholar
  95. (95).
    Sun CA, Lai HC, Chang CC, et al.: The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix.Gynecologic Oncology. 2001,83:95–99.PubMedCrossRefGoogle Scholar
  96. (96).
    Kirwan JM, Herrington CS: Human papillomavirus and cervical cancer: Where are we now?British Journal of Obstetrics and Gynaecology. 2001,108:1204–1213.PubMedCrossRefGoogle Scholar
  97. (97).
    Winkelstein {jrJr.} W: Smoking and cervical cancer—current status: A review.American Journal of Epidemiology. 1990,131:945–957.PubMedGoogle Scholar
  98. (98).
    Szarewski A, Jarvis MJ, Sasieni P, et al.: Effect of smoking cessation on cervical lesion size.Lancet. 1996,347:941–943.PubMedCrossRefGoogle Scholar
  99. (99).
    Castle PE, Wacholder S, Lorincz AT, et al.: A prospective study of high-grade cervical neoplasia risk among human papillo-mavirus-infected women.Journal of the National Cancer Institute. 2002,94:1406–1414.PubMedGoogle Scholar
  100. (100).
    Kjellberg L, Hallmans G, Ahren AM, et al.: Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection.British Journal of Cancer. 2000,82:1332–1338.PubMedCrossRefGoogle Scholar
  101. (101).
    Hildesheim A, Herrero R, Castle PE, et al.: HPV cofactors related to the development of cervical cancer: Results from a population-based study in Costa Rica.British Journal of Cancer. 2001,84:1219–1226.PubMedCrossRefGoogle Scholar
  102. (102).
    Ho GY, Kadish AS, Burk RD, et al.: HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia.International Journal of Cancer. 1998,78:281–285.CrossRefGoogle Scholar
  103. (103).
    Marteau TM, Hankins M, Collins B: Perceptions of risk of cervical cancer and attitudes towards cervical screening: A comparison of smokers and non-smokers.Family Practice. 2002,19:18–22.PubMedCrossRefGoogle Scholar
  104. (104).
    Orbell S, Crombie I, Robertson A, Johnston G, Kenicer M: Assessing the effectiveness of a screening campaign: Who is missed by 80% cervical screening coverage?Journal of theRoyal Society of Medicine. 1995,88:389–394.Google Scholar
  105. (105).
    McBride CM, Scholes D, Grothaus LC, et al.: Evaluation of a minimal self-help smoking cessation intervention following cervical cancer screening.Preventive Medicine. 1999,29:133–138.PubMedCrossRefGoogle Scholar
  106. (106).
    Marteau TM, Rana S, Kubba A: Smoking and cervical cancer: A qualitative study of the explanatory models of smokers with cervical abnormalities.Psychology, Health and Medicine. 2002,7:107–109.CrossRefGoogle Scholar
  107. (107).
    Kobayashi A, Miaskowski C, Wallhagen M, Smith-McCune K: Recent developments in understanding the immune response to human papilloma virus infection and cervical neoplasia.Oncology Nursing Forum. 2000,27:643–651.PubMedGoogle Scholar
  108. (108).
    Tjiong MY, Out TA, Ter Schegget J, Burger MP, Van Der Vange N: Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: a review.International Journal of Gynecological Cancer. 2001,11:9–17.PubMedCrossRefGoogle Scholar
  109. (109).
    Luxton J, Shepherd P: Human papillomavirus antigens and T-cell recognition.Current Opinion in Infectious Diseases. 2001,14:139–143.PubMedCrossRefGoogle Scholar
  110. (110).
    Brown MR, Noffsinger A, First MR, Penn I, Husseinzadeh N: HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients.Gynecologic Oncology. 2000,79:220–224.PubMedCrossRefGoogle Scholar
  111. (111).
    Herbert TB, Cohen S: Stress and immunity in humans: A meta-analytic review.Psychosomatic Medicine. 1993,55:364–379.PubMedGoogle Scholar
  112. (112).
    Kiecolt-Glaser JK, McGuire L, Robles TF, Glaser R: Psychoneuroimmunology and psychosomatic medicine: Back to the future.Psychosomatic Medicine. 2002,64:15–28.PubMedGoogle Scholar
  113. (113).
    Antoni MH, Goodkin K: Host moderator variables in the promotion of cervical neoplasia—I. Personality facets.Journal of Psychosomatic Research. 1988,32:327–338.PubMedCrossRefGoogle Scholar
  114. (114).
    Antoni MH, Goodkin K: Host moderator variables in the promotion of cervical neoplasia—II. Dimensions of life stress.Journal of Psychosomatic Research. 1989,33:457–467.PubMedCrossRefGoogle Scholar
  115. (115).
    Visser AP, Goodkin K, Vingerhoets AJJM, et al.: Cervical cancer: psychosocial and psychoneuroimmunological issues. In Goodkin K, Visser AP (eds),Psychoneuroimmunology: Stress, Mental Disorders, and Health. Washington, DC: American Psychiatric Press, 2000, 41–75.Google Scholar
  116. (116).
    PereiraDB, AntoniMH, Danielson A, et al.: Life stress and cervical squamous intraepithelial lesions in women with human papillomavirus and human immunodeficiency virus.Psychosomatic Medicine. 2003,65:427–434.CrossRefGoogle Scholar
  117. (117).
    Coker AL, Bond S, Madeleine MM, Luchok K, Pirisi L: Psychosocial stress and cervical neoplasia risk.Psychosomatic Medicine. 2003,65:644–651.PubMedCrossRefGoogle Scholar
  118. (118).
    Kiecolt-Glaser JK, Dura JR, Speicher CE, Trask OJ, Glaser R: Spousal caregivers of dementia victims: longitudinal changes in immunity and health.Psychosomatic Medicine. 1991,53:345–362.PubMedGoogle Scholar
  119. (119).
    Moreno V, Bosch FX, Munoz N, et al.: Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study.Lancet. 2002,359:1085–1092.PubMedCrossRefGoogle Scholar
  120. (120).
    Smith JS, Munoz N, Herrero R, et al.: Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines.Journal of Infectious Diseases. 2002,185:324–331.PubMedCrossRefGoogle Scholar
  121. (121).
    Sedjo RL, Inserra P, Abrahamsen M, et al.: Human papillomavirus persistence and nutrients involved in the methylation pathway among a cohort of young women.Cancer Epidemiology, Biomarkers and Prevention. 2002,11:353–359.PubMedGoogle Scholar
  122. (122).
    Potischman N, Brinton LA: Nutrition and cervical neoplasia.Cancer Causes and Control. 1996,7:113–126.PubMedCrossRefGoogle Scholar
  123. (123).
    Hall S, Bishop AJ, Marteau TM: Increased readiness to stop smoking in women undergoing cervical screening: Evaluation of two leaflets.Nicotine and Tobacco Research (in press, 2003).Google Scholar
  124. (124).
    McBride CM, Scholes D, Grothaus L, Curry SJ, Albright J: Promoting smoking cessation among women who seek cervical cancer screening.Obstetrics and Gynecology. 1998,91:719–724.PubMedCrossRefGoogle Scholar
  125. (125).
    Cruess S, Antoni M, Cruess D, et al.: Reductions in herpes simplex virus type 2 antibody titers after cognitive behavioral stress management and relationships with neuroendocrine function, relaxation skills, and social support in HIV- positive men.Psychosomatic Medicine. 2000,62:828–837.PubMedGoogle Scholar
  126. (126).
    Cothran MM, White JP: Adolescent behavior and sexually transmitted diseases: the dilemma of human papillomavirus.Health Care for Women International. 2002,23:306–319.PubMedCrossRefGoogle Scholar
  127. (127).
    Manhart LE, Koutsky LA: Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis.Sexually Transmitted Diseases. 2002,29:725–735.PubMedCrossRefGoogle Scholar
  128. (128).
    Rousseau MC, Franco EL, Villa LL, et al.: A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections.Cancer Epidemiology, Biomarkers and Prevention. 2000,9:469–476.PubMedGoogle Scholar
  129. (129).
    Peyton CL, Gravitt PE, Hunt WC, et al.: Determinants of genital human papillomavirus detection in a US population.Journal of Infectious Diseases. 2001,183:1554–1564.PubMedCrossRefGoogle Scholar
  130. (130).
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women.New England Journal of Medicine. 1998,338:423–428.PubMedCrossRefGoogle Scholar
  131. (131).
    Lazcano-Ponce E, Herrero R, Munoz N, et al.: Epidemiology of HPV infection among Mexican women with normal cervical cytology.International Journal of Cancer. 2001,91:412–420.CrossRefGoogle Scholar
  132. (132).
    Kjaer SK, Engholm G, Teisen C, et al.: Risk factors for cervical human papillomavirus and herpes simplex virus infections in Greenland and Denmark: A population-based study.American Journal of Epidemiology. 1990,131:669–682.PubMedGoogle Scholar
  133. (133).
    Castellsague X, Bosch FX, Munoz N, et al.: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners.New England Journal of Medicine. 2002,346:1105–1112.PubMedCrossRefGoogle Scholar
  134. (134).
    Adami HO, Trichopoulos D: Cervical cancer and the elusive male factor.New England Journal of Medicine. 2002,346:1160–1161.PubMedCrossRefGoogle Scholar
  135. (135).
    Anttila T, Saikku P, Koskela P, et al.: Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.Journal of the American Medical Association. 2001,285:47–51.PubMedCrossRefGoogle Scholar
  136. (136).
    Zenilman JM: Chlamydia and cervical cancer: A real association?Journal of the American Medical Association. 2001,285:81–83.PubMedCrossRefGoogle Scholar
  137. (137).
    Gravitt PE, Castle PE: Chlamydia trachomatis and cervical squamous cell carcinoma.Journal of the American Medical Association. 2001,285:1703–1704.PubMedCrossRefGoogle Scholar
  138. (138).
    Reesink-Peters N, Ossewaarde JM, Van Der Zee AG, et al.: No association of anti-Chlamydia trachomatis antibodies and severity of cervical neoplasia.Sexually Transmitted Infections. 2001,77:101–102.PubMedCrossRefGoogle Scholar
  139. (139).
    Shepherd J, Weston R, Peersman G, Napuli IZ: Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer.Cochrane Database Systematic Review. 2000, CD001035.Google Scholar
  140. (140).
    Braun V, Gavey N: Exploring the possibility of sexual-behavioural primary prevention interventions for cervical cancer.Australian and New Zealand Journal of Public Health. 1998,22:353–359.PubMedGoogle Scholar
  141. (141).
    Braun V, Gavey N: “With the best of reasons”: Cervical cancer prevention policy and the suppression of sexual risk factor information.Social Science and Medicine. 1999,48:1463–1474.PubMedCrossRefGoogle Scholar
  142. (142).
    National Health Service: Cervical Screening: The Facts. London: Health Promotion England, 2001. Retrieved November 3, 2003, from http://www.cancerscreening.nhs.uk/cervial/publications/nhscsp-informed-choice.pdfGoogle Scholar

Copyright information

© The Society of Behavioral Medicine 2004

Authors and Affiliations

  • Jo Waller
    • 1
  • Kirsten J. McCaffery
    • 1
  • Sue Forrest
    • 1
  • Jane Wardle
    • 1
  1. 1.Cancer Research UK Health Behaviour Unit, Department of Epidemiology & Public HealthUniversity College LondonLondonUK

Personalised recommendations